The first commercial batch of COVAXIN released on Ankleshwar is a milestone, says Mandaviya

Gujarat, August 29, 2021:

Released the first commercial batch of COVAXIN manufactured in Ankleshwar, the production capacity of COVID-19 administration of 1 chlore or more per month from today, Mansukh Mandaviya Union Minister of Health increased the production capacity of COVID vaccine Is a further impetus for the pace of vaccination in India.

At the inauguration, Mandaviya said India is implementing one of the world’s largest vaccination programs, made possible by the development of these unique vaccines. The National COVID-19 Vaccination Program has been successfully implemented in all states and Union Territory since 16 January 2021.

Health Minister Union dedicated the release of the first batch of COVAXIN from the Uncleshwar facility to the country, “This is a milestone in India’s battle journey against COVID-19. Production of the COVID-19 vaccine. Increased capacity will give further impetus to the pace of vaccination in India. “

He added that the research and manufacture of two vaccines, Bharat Biotech and Zydus Cadila, in India is a matter of great pride. He also reported that the Ankleshwar plant has a production capacity of more than one chlore per month starting today.

Talking about India’s contribution to the fight against the pandemic, Mandaviya said India is always at the forefront of helping other countries in need of essential medicines to address the COVID situation. ..

Regarding the status of COVAXIN production in India, the Federal Minister said that Bharat Biotech has already deployed multiple production lines on the Hyderabad, Marul, Bangalore and Pune campuses, and with the addition of Chiron Behring, Ankleshwar has COVAXIN. Announced that it will further increase its production capacity. ..

“A new filing facility built in 2020 is currently being used to produce COVAXIN. Production of COVAXIN will begin in early June, before the team will carry out an engineering batch to study the facility’s equipment functions. Products manufactured from the Ankleshwar facility will be available from September 2021. “

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, said: “Our goal of developing a vaccine with global safety and efficacy standards has been achieved.

“We are looking for manufacturing partnerships with partners in other countries who have prior expertise in the commercial scale production of inactivated viral vaccines under biosafety containment for further enhancement.” He added. ET Health